Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02624219 · ClinicalTrials.gov registry record · Phase 1
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 276
- Enrollment target
NCT02624219: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02624219 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 276 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (360% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02624219, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 276 participants
- Enrollment target
Study Summary
This is a Phase I randomized, double-blind, controlled trial in 275 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine manufactured by bioCSL administered at different dosages (7.5 or 15 mcg of HA/0.5 mL dose) given with or without AS03 or MF59 adjuvants manufactured by GlaxoSmithKline Biologicals and Novartis Vaccines and Diagnostics, respectively.
Interventions
- DRUG AS03
- BIOLOGICAL Monovalent Influenza A/H5N8 vaccine
- DRUG MF59 adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2016-08-16 |
| Est. Completion | 2018-01-30 |
| Phase | Phase 1 |
What the finished NCT02624219 record still lists
NCT02624219 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (360% higher).
The record links to 0 conditions, and to 3 interventions - of which AS03 is the first listed.
NCT02624219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02624219 about?
NCT02624219 is a clinical study titled "H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults". This is a Phase I randomized, double-blind, controlled trial in 275 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of a monovalent inacti...
What is the current status of trial NCT02624219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 276 participants. The study started on 2016-08-16. Estimated completion is 2018-01-30.
What interventions are being tested in trial NCT02624219?
The interventions under investigation include: AS03 (DRUG), Monovalent Influenza A/H5N8 vaccine (BIOLOGICAL), MF59 adjuvant (DRUG).
Who is sponsoring clinical trial NCT02624219?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02624219's enrollment target sits among peer trials
276 148th of 2000 higher than 1,852 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI